Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Polyunsaturated fatty acids control lipid membrane dynamics and ferroptosis sensitivity in B-cell lymphoma

Etienne Leveille, Eden Bramson, Mark Robinson et al. Nov 03, 2025 pp. 5094-5094 10.1182/blood-2025-5094

Abstract Background and Significance: Induction of ferroptosis, a form of cell death driven by iron-dependent peroxidation of polyunsaturate...

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Luciano Costa, Susan Bal, Kelly Godby et al. Nov 03, 2025 pp. 1037-1037 10.1182/blood-2025-1037

Abstract Introduction Functional high-risk MM (FHR) is currently defined as relapse within 18 month (mo) of induction therapy irrespective o...

Diagnostic conformity to who criteria and use of cytoreductive therapy in classical myeloproliferative neoplasms: Experience from a resource-limited country

Sayanthan Sivakumaran, Ahalyaa Sivashangar, Visaka Ratnamalala et al. Nov 03, 2025 pp. 7324-7324 10.1182/blood-2025-7324

Abstract Background: Classical myeloproliferative neoplasms (MPNs); polycythemia vera (PV), essential thrombocythemia (ET) and primary myelo...

Racial and socioeconomic disparities in incidence and survival of splenic marginal zone lymphoma :  United States national database analysis

Pragya Jain, Nency Ganatra, Shivam Patel et al. Nov 03, 2025 pp. 7095-7095 10.1182/blood-2025-7095

Abstract Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent B cell neoplasm. There has been limited in...

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Maria Carmen Martinez Munoz, Raúl Córdoba, Rosa Maria Rodriguez Nunez et al. Nov 03, 2025 pp. 3621-3621 10.1182/blood-2025-3621

Abstract INTRODUCTION Older adults (≥60 years) represent up to a quarter of all classic Hodgkin lymphoma (cHL) cases in Western countries and...

Effectiveness of thrombopoietin (TPO) in stem cell mobilization for multiple myeloma and lymphoma patients

Rongxia Wei, Jingrui Sui, Lijing Mao et al. Nov 03, 2025 pp. 7700-7700 10.1182/blood-2025-7700

Abstract Background: Thrombopoietin (TPO) shows promise for hematopoietic stem cell mobilization. This study evaluated TPO as a single-agent...

PROK1 locus variant identified as a genetic determinant of anthracycline-related cardiomyopathy in long-term childhood acute leukemia survivors

Mathilde Veneziano Broccia, Gerard Michel, Julie Berbis et al. Nov 03, 2025 pp. 1586-1586 10.1182/blood-2025-1586

Abstract Introduction Survival rates for childhood and adolescent acute leukemia have significantly improved over the pa...

Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant

Smita Hiwase, Alia Cibich, Leanne Purins et al. Nov 03, 2025 pp. 2508-2508 10.1182/blood-2025-2508

Abstract Background: Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative therapy for high-risk he...

Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study

Peiqi Zhao, Yulan Zhou, Lihua Qiu et al. Nov 03, 2025 pp. 1809-1809 10.1182/blood-2025-1809

Abstract Background Targeted therapy-based induction regimens provide novel treatment options for newly diagnosed mantle...

A novel spontaneous HLH mouse model by engrafting human HSCs into b-ndg MGMT3 mice

Yanhui Nie, Ruili Lv, Chengzhang Shang et al. Nov 03, 2025 pp. 1204-1204 10.1182/blood-2025-1204

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome with an...

Functional inactivation of duodenal ferroportin by hepcidin drives iron-dependent degradation of DMT1 in lysosomes

Angeliki Katsarou, Apostolos Galaris, Carine Fillebeen et al. Nov 03, 2025 pp. 4678-4678 10.1182/blood-2025-4678

Abstract Hepcidin regulates systemic iron homeostasis by inhibiting iron absorption and recycling through degradation of the iron exporter f...

PORT-77 is a potent inhibitor of ABCG2 that reduces efflux of protoporphyrin IX from erythrocytes of patients with protoporphyria and reduces plasma protoporphyrin IX levels in healthy human subjects

Bhavik Shah, Edmond Huang, Yvonne Pak et al. Nov 03, 2025 pp. 4663-4663 10.1182/blood-2025-4663

Abstract Background: PORT-77 is a novel, orally bioavailable inhibitor of the ATP-binding cassette subfamily G member 2...

Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes

Asmita Shukla, Jeff Justin Aguilar, Vikramjit Dhillon et al. Nov 03, 2025 pp. 3872-3872 10.1182/blood-2025-3872

Abstract Introduction Mutations incorporated risk stratification tool in MDS (IPSS-M) have offered greater prognostic pr...

Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma

Abdul Rafae Faisal, Mohammad Faizan, Abdullah Humayun et al. Nov 03, 2025 pp. 7577-7577 10.1182/blood-2025-7577

Abstract Introduction Teclistamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, and the...

The role of hematopoietic stem cell transplantation in peripheral T-cell lymphoma not otherwise specified

Firas Baidoun, Mahmood Aldapt, Muhamad Alhaj Moustafa Nov 03, 2025 pp. 7150-7150 10.1182/blood-2025-7150

Abstract Introduction Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma...

Discovery and preclinical characterization of SB-01, a novel allosteric inhibitor of human factor XIa

Chiranjeev Sharma, Rama Gunta, Rawan Fayyad et al. Nov 03, 2025 pp. 16-16 10.1182/blood-2025-16

Abstract Human factor XI (hFXI) is a key protein in the intrinsic coagulation pathway that amplifies clot formation under pathological condi...

Red cell rheology predicts acute chest syndrome and vaso-occlusive events in sickle cell disease

Ashwin Patel, Ugochukwu Agbakwuru, Akshay Patwardhan et al. Nov 03, 2025 pp. 1152-1152 10.1182/blood-2025-1152

Abstract Sickle cell disease (SCD) is an autosomal recessive disorder characterized by rigid, poorly deformable red blood cells (RBC); worse...

Venetoclax pharmacokinetics with triazole prophylaxis in patients with Acute Myeloid Leukemia in India: Pilot study

Chepsy Philip, Aswin Nair, Aakash Chozakade et al. Nov 03, 2025 pp. 6784-6784 10.1182/blood-2025-6784

Abstract Venetoclax (VEN) combined with a hypomethylating agent is standard induction therapy for patients with acute myeloid leukemia (AML)...

Feasibility of characterizing von Willebrand disease using high-throughput affinity-based proteomics

Rocio Vacik Diaz, Melanie Daniel, Pierre Boisseau et al. Nov 03, 2025 pp. 6635-6635 10.1182/blood-2025-6635

Abstract Background: Von Willebrand disease (VWD) is the most common inherited bleeding disorder, caused by quantitative or qualitative defe...

Frailty as a prognostic factor in younger adult patients with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Sergio Rodriguez-Rodriguez, Nihar Desai, Maria Queralt Salas Gay et al. Nov 03, 2025 pp. 4430-4430 10.1182/blood-2025-4430

Abstract Introduction Acute myeloid leukemia (AML) is potentially curable with allogeneic stem cell transplantation (alloHCT); however, its...

Atypical neurotoxicity in CAR-T cell therapy: A retrospective analysis of unusual icans presentations and their clinical implications

Melissa Nicholas, Abdulaziz Abu Haimed, Faisal Abushullaih et al. Nov 03, 2025 pp. 4151-4151 10.1182/blood-2025-4151

Abstract Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy is a transformative treatment for relapsed/refractory Non-Hodgkin Lymp...

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Dominique Mosley, Richa Parikh, Sara Scott et al. Nov 03, 2025 pp. 3968-3968 10.1182/blood-2025-3968

Abstract AL amyloidosis is a rare but life-threatening plasma cell disorder characterized by the deposition of misfolded immunoglobulin ligh...

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Jian Li, Mark Dowling, Anthony Jeffrey et al. Nov 03, 2025 pp. 2779-2779 10.1182/blood-2025-2779

Abstract Aim: Richter transformation (RT) is an uncommon (2-10%) complication of chronic lymphocytic leukemia (CLL), most frequently manifes...

Docirbrutinib (AS-1763), a novel non-COVALENT BTK inhibitor, demonstrates efficacy in BTK inhibitor-resistant mutant cells

Tokiko Asami, Hitomi Fujiwara, Hiroko Endo et al. Nov 03, 2025 pp. 5077-5077 10.1182/blood-2025-5077

Abstract Background: Bruton's tyrosine kinase inhibitors are a standard therapy for chronic lymphocytic leukemia (CLL). Despite their effica...

Travel distance to treatment center does not independently impact survival in Acute Myeloid Leukemia (AML): A national cancer database (NCDB) analysis

Ann Mercurio, Thomas Chen, Dahniel Sastow et al. Nov 03, 2025 pp. 293-293 10.1182/blood-2025-293

Abstract Introduction AML is an aggressive hematologic malignancy that requires frequent hospitalizations, close monitoring, and complex sup...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page